January 20, 2020 Scientists at Los Alamos and international partners have created the first 3-D images of a special type of RNA molecule that is critical for stem cell programming and known as the dark matter of the genome.
As far as we know, said corresponding author Karissa Sanbonmatsu, Ph.D.,this is the first full 3-D structural study of any long, non-coding RNA (lncRNA) other than a partial structure. Sanbonmatsu is a structural biologist at Los Alamos National Laboratory. A better understanding of these RNAs could lead to new strategies in regenerative medicine for people with heart conditions due to cardiovascular disease or aging.
The team used a technique called small angle X-ray scattering (SAXS) that reveals the 3-D envelope of the RNA molecule, according to Trushar Patel, a Canadian professor on the team. Next, with the help of machine learning and high-performance computing, they made atomistic models to fit inside the envelopes this included the creation of an atomistic model that is also the longest of an isolated RNA (636 nucleotides) to date, said Doo Nam Kim, lead author on the Nature Communications paper.[1]
Our work represents the first step in showing that these difficult-to-image RNAs do possess 3-D structures, and that these molecular structures may very well determine how they operate, said Sanbonmatsu. The RNA studied is called Braveheart it triggers the transformation of stem cells into heart cells, she said.
Before the human genome was sequenced in 2000, it was thought that it mostly contained instructions for proteins, the workhorse molecules of human cells. Scientists were shocked to discover that less than 10 percent of the genome encoded proteins. Ever since, the other 90 percent was deemed to be junk DNA or dark matter. Enter RNA, the molecular cousin of DNA. Scientists originally assumed the main purpose of RNA was simply to coordinate as a messenger for DNA in the synthesis of proteins. However, it has recently been shown that more than 90 percent of the genome encodes a new and mysterous class of RNAs, called long non-coding RNA molecules (lncRNA).
These RNA molecules help to control the turning on and off of genes; their malfunction causes birth defects, autism and even cancer in some cases. They are also key to reprogramming adult stem cells. Even though the molecules make up 90 percent of the genome, scientists have almost no idea how they work, or even what they look like. In this study, one of the largest RNA-only 3-D studies, the new 3-D images sets the stage for future studies that will shed more light on how they control genes.
Funding for this project was provided by the National Institutes of Health (NIH), Los Alamos Institutional Computing and Los Alamos Laboratory Directed R&Dand; Diamond Light Source (U.K.).
Learn more about theSanbonmatsu Team at Los Alamos.
Reference:
1.Karissa Y. Sanbonmatsu, Doo Nam Kim and Scott P. Hennelly of Los Alamos National Laboratory and New Mexico Consortium; Bernhard C. Thiel and Ivo L. Hofacker of University of Vienna, Austria; Tyler Mrozowich and Trushar R. Patel of University of Lethbridge, Canada. Zinc-finger protein CNBP alters the 3-D structure of lncRNA Braveheart in solution Authors: Nature Communications, DOI 10.1038/s41467-019-13942-4.
Here is the original post:
Scientists Image Heart RNA Structure for the First Time - Diagnostic and Interventional Cardiology
- MS in Stem Cell Biology and Regenerative Medicine - January 17th, 2022
- Home | Eli and Edythe Broad Center of Regeneration ... - January 17th, 2022
- Rising Focus on Exploring Potential of Stem Cells as Therapeutic Tools in Drug Targeting and Regenerative Medicine to Fuel Revenue Growth of Stem... - January 17th, 2022
- Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis - OncLive - January 17th, 2022
- Companies In The Regenerative Medicine For Cartilage Market Increase R&D; On Gene Therapy Technique As Per - Benzinga - January 17th, 2022
- Regenerative Medicine: The Promise Of Undoing The Ravages Of Time - Hackaday - January 17th, 2022
- CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes -... - November 22nd, 2021
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2021-2028 - Increasing Demand for Body Reconstruction Procedures and Tissue Engineering -... - November 22nd, 2021
- Researchers use model of hypothalamus to implicate genes associated with sleep, BMI, puberty, and more - EurekAlert - November 22nd, 2021
- COVID-19: Researchers warn against overhyping early-stage therapies - Medical News Today - October 28th, 2021
- Albert Einstein Cancer Center researcher receives NCI Outstanding Investigator Award to study two deadly blood diseases - EurekAlert - October 28th, 2021
- San Diego research centers receive $15 million to train next generation of scientists - Three San Diego research institutions have been awarded nearly... - October 28th, 2021
- Medical Innovation In Pet Healthcare Is Taking Things Up a Notch - Entrepreneur - October 28th, 2021
- UC Davis Medical Center faculty respond to the rise of treatments like Merck's anti-COVID pill - The Aggie - The Aggie - October 28th, 2021
- Managing superficial pyoderma with light therapy - DVM 360 - October 28th, 2021
- Completion of Enrollment in Phase III Comparative Study for Investigational Regenerative Cellular Medicine (gMSC1) for Knee Chondrogenesis Using... - October 28th, 2021
- New Stem Cell Approach Through Using Wavelength Laser Might have Discovered Why Humans Lose Hair - Tech Times - October 5th, 2021
- Stem cells and their role in lung transplant rejection - Michigan Medicine - October 5th, 2021
- Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial - KMVT - October 5th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WIBW - October 5th, 2021
- Diabetic patient receives stem cell therapy - The Hindu - August 18th, 2021
- COVID- 19 Third Dose Approved for Certain Immunocompromised Individuals - the City of Cambridge - August 18th, 2021
- Acute Myeloid Leukemia Treatment: What You Need to Know - Healthline - August 18th, 2021
- 3D Bioprinting Market Size to Reach USD 2,687.8 Million in 2027 | Increasing Use of 3D Bioprinters in Medical Procedures, Training and Testing Along... - August 18th, 2021
- Some Residents Should Consider Third COVID-19 Vaccine Dose - Wyoming Department of Health - August 18th, 2021
- Stem Cell Alopecia Treatment Market Size, Demand, Growth, Trends, Segmentation and Forecasts to 2028 - The Market Writeuo - The Market Writeuo - August 18th, 2021
- Head-To-Head Phase 3 Trial To Evaluate BTK Inhibitors in MCL - Targeted Oncology - August 18th, 2021
- Safety of Stem Cell Therapy for Chronic Knee Pain Confirmed in New Study - SciTechDaily - August 5th, 2021
- Asia-Pacific Cell Therapy Market8 - Opportunities in the Approval of Kymriah and Yescarta - Markets Insider - August 5th, 2021
- Background should not be a barrier to access stem cell transplant treatment and care - PoliticsHome - August 5th, 2021
- Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy |... - August 5th, 2021
- Gliomagenesis is orchestrated by the Oct3/4 regulatory network. - Physician's Weekly - August 5th, 2021
- Improving the Treatment Gap in Diffuse Large B-Cell Lymphoma - Targeted Oncology - August 5th, 2021
- Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress - StreetInsider.com - August 5th, 2021
- MUHS, Nashik to conduct fellowship course in regenerative medicine - BSI bureau - August 5th, 2021
- FDA Hands Out Surprising Rejection of Meduxus and Medac's Treosulfan - BioSpace - August 5th, 2021
- Dr. Flowers on Efforts to Improve Frontline Treatment in DLBCL - OncLive - August 5th, 2021
- Future Directions in the Treatment of Polycythemia Vera - OncLive - August 5th, 2021
- FDA Grants Priority Review to Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer - Business Wire - August 5th, 2021
- Cellino Appoints Industry Pioneer Robert J. Palay to the Board - Business Wire - August 5th, 2021
- Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF- Superfamily Member for the Treatment of Cancer - Yahoo Finance - August 5th, 2021
- Stemming the tide of stem-cell treatment scams - Houston Chronicle - July 22nd, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 22nd, 2021
- John Theurer Cancer Center Investigators Participated in ZUMA-7 Study Showing Value of CAR T-Cell Therapy as Second-Line Treatment for Relapsed Large... - July 22nd, 2021
- Creative Medical Technology Holdings Announces MyeloCelz The Company's Second Regenerative Immunotherapy Product - PRNewswire - July 22nd, 2021
- Kadimastem Patent for cell selection of beta cells to Treat and Potentially Cure Diabetes was Granted in Japan - Yahoo Eurosport UK - July 22nd, 2021
- Bluebird, with little fanfare, is first to bring a second gene therapy to market - BioPharma Dive - July 22nd, 2021
- BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson's Disease - Yahoo Finance - July 22nd, 2021
- ViaCyte Appoints Dr. Jon Wilensky as Head of Surgery - PRNewswire - July 22nd, 2021
- Emerging Quadruplets, Novel Targets, and Immunotherapy Advances Personalized Medicine in Multiple Myeloma - OncLive - July 22nd, 2021
- Beyond CAR-T: New Frontiers in Living Cell Therapies - UCSF News Services - July 7th, 2021
- Sleeper cells, cells of origin and hematopoietic stem cells - Brain Tumour Research - July 7th, 2021
- Marker Therapeutics Announces Completion of Safety Lead-In Portion of Phase 2 Study in Post-Transplant AML - PRNewswire - July 7th, 2021
- Researchers investigate whether stem cell therapy is safe and effective for treatment-resistant bipolar disease - Newswise - April 18th, 2021
- Stem Cell and Regenerative Therapy Market: Cell Therapy Segment to Dominate Global Market - BioSpace - April 18th, 2021
- First in the nation, FDA-approved Phase II mesenchymal stem cell therapy for Parkinson's disease begins - Newswise - April 18th, 2021
- Cellino Biotech developing tech to help scale stem cell therapies - MedCity News - April 18th, 2021
- Stem cell treatment needed to fight the good fight - Victoria Lookout - April 18th, 2021
- Being bionic: the future of regenerative medicine - Toronto Star - April 18th, 2021
- Treating chronic myeloid leukemia (CML): By phase and more - Medical News Today - April 18th, 2021
- Chemical conversion of human epidermal stem cells into intestinal goblet cells for modeling mucus-microbe interaction and therapy - Science Advances - April 18th, 2021
- Andres Isaias Combining Innovation and Excellence - Influencive - April 18th, 2021
- A Massive New Gene Editing Project Is Out to Crush Alzheimer's - Singularity Hub - April 18th, 2021
- Antibiotic Use Prior to Allogeneic Stem Cell Transplantation May Be Linked to Graft Vs Host Disease - Hematology Advisor - April 18th, 2021
- Mucopolysaccharidosis (MPS) Treatment Market Is Rising With Post COVID-19 Impact Analysis, Development, CAGR - Global Banking And Finance Review - April 18th, 2021
- The Recovery Room: News beyond the pandemic April 16 - Medical News Today - April 18th, 2021
- The Governments Watchful Eye on Fraud Stemming from Stem Cell Therapy - JD Supra - April 4th, 2021
- Uprooting Cancer: Innovative Hydrogel Rapidly Reverts Cancer Cells Back to Cancer Stem Cells - SciTechDaily - April 4th, 2021
- Multiple sclerosis: Recent research on causes and treatments - Medical News Today - April 4th, 2021
- First CAR T-Cell Therapy for Multiple Myeloma: Abecma - Medscape - April 4th, 2021
- Vitro Biopharma Retains Leading Health Care Executive as Acting Director of Regulatory Affairs & Director - Benzinga - April 4th, 2021
- Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy - DocWire News - April 4th, 2021
- Orca-T Offers an Alternative to HSCT With Improved Patient Experience - OncLive - April 4th, 2021
- Russell Health Highlighted in the Silicon Review's '50 Leading Companies of the Year 2021' - PRNewswire - April 4th, 2021
- Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy... - April 4th, 2021
- LGL Leukemia: Overview, Symptoms, and Treatment - Healthline - April 4th, 2021
- Funding the Next Generation of Cancer Therapies - Genetic Engineering & Biotechnology News - April 4th, 2021
- RenovaCare Announces Organizational Changes and Appointment of New Officers - GlobeNewswire - April 4th, 2021
- Stem Cell Therapy Market expected to reach USD 16.51 Billion by 2025 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - March 8th, 2021
- Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine... - March 8th, 2021
